scholarly journals Higher Serum Thyroid Stimulating Hormone Level in Thyroid Nodule Patients Is Associated with Greater Risks of Differentiated Thyroid Cancer and Advanced Tumor Stage

2008 ◽  
Vol 93 (3) ◽  
pp. 809-814 ◽  
Author(s):  
Megan Rist Haymart ◽  
Daniel John Repplinger ◽  
Glen E. Leverson ◽  
Diane F. Elson ◽  
Rebecca S. Sippel ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Nodule ◽  
Differentiated Thyroid Cancer ◽  
Hormone Level ◽  
Tumor Stage ◽  
Thyroid Stimulating Hormone ◽  
Advanced Tumor Stage ◽  
Advanced Tumor ◽  
Stimulating Hormone

scholarly journals Circulating thyroid stimulating hormone receptor messenger RNA and differentiated thyroid cancer: A diagnostic meta-analysis

Oncotarget ◽  
2016 ◽  
Vol 8 (4) ◽  
pp. 6623-6629 ◽  
Author(s):  
Zhen-Zhen Zhang ◽  
Qiang Chen ◽  
Chao-Yue Kong ◽  
Zhan-Ming Li ◽  
Li-Shun Wang
Keyword(s):  
Thyroid Cancer ◽  
Hormone Receptor ◽  
Messenger Rna ◽  
Differentiated Thyroid Cancer ◽  
Meta Analysis ◽  
Thyroid Stimulating Hormone ◽  
Stimulating Hormone

scholarly journals CD74 expression and its therapeutic potential in thyroid carcinoma

2015 ◽  
Vol 22 (2) ◽  
pp. 179-190 ◽  
Author(s):  
Shih-Ping Cheng ◽  
Chien-Liang Liu ◽  
Ming-Jen Chen ◽  
Ming-Nan Chien ◽  
Ching-Hsiang Leung ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Therapeutic Potential ◽  
Thyroid Tissue ◽  
Anaplastic Thyroid Cancer ◽  
Tumor Stage ◽  
Migration And Invasion ◽  
Advanced Tumor Stage ◽  
Papillary Thyroid ◽  
Extrathyroidal Invasion ◽  
Advanced Tumor

CD74, the invariant chain of major histocompatibility complex class II, is also a receptor for macrophage migration inhibitory factor (MIF). CD74 and MIF have been associated with tumor progression and metastasis in hematologic and solid tumors. In this study, we found that 60 and 65% of papillary thyroid cancers were positive for CD74 and MIF immunohistochemical staining respectively. Anaplastic thyroid cancer was negative for MIF, but mostly positive for CD74 expression. Normal thyroid tissue and follicular adenomas were negative for CD74 expression. CD74 expression in papillary thyroid cancer was associated with larger tumor size (P=0.043), extrathyroidal invasion (P=0.021), advanced TNM stage (P=0.006), and higher MACIS score (P=0.026). No clinicopathological parameter was associated with MIF expression. Treatment with anti-CD74 antibody in thyroid cancer cells inhibited cell growth, colony formation, cell migration and invasion, and vascular endothelial growth factor secretion. In contrast, treatment with recombinant MIF induced an increase in cell invasion. Anti-CD74 treatment reduced AKT phosphorylation and stimulated AMPK activation. Our findings suggest that CD74 overexpression in thyroid cancer is associated with advanced tumor stage and may serve as a therapeutic target.

Differentiated Thyroid Cancer

2019 ◽  
Author(s):  
Rebecca Tuttle ◽  
William Cance ◽  
James Howe
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Nodule ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Kinase Inhibitors ◽  
Needle Aspiration ◽  
Thyroid Stimulating Hormone ◽  
Diagnostic Modality ◽  
Radioactive Iodine Ablation ◽  
Common Malignancy

Differentiated thyroid cancer is a common malignancy with an excellent prognosis. Patients typically present with a thyroid nodule identified on physical exam or imaging. Fine needle aspiration (FNA) is the diagnostic modality of choice; ultrasound of the neck is used preoperatively to evaluate lymphadenopathy. Surgery is the mainstay of treatment, with partial or total thyroidectomy (with or without lymphadenectomy). Intra-operatively, identification of the recurrent laryngeal nerve and preservation of the parathyroid glands is imperative. Postoperatively, patients are considered for adjuvant radioactive iodine ablation. Risk stratification systems are available to assist patient selection for therapy. Surveillance is completed with serial physical exams, laboratory studies, ultrasound, and radioactive iodine scanning. Recurrence can be managed with surgery, thyroid-stimulating hormone suppression, radioactive iodine ablation, radiation, or kinase inhibitors.  This review contains 8 figures, 6 tables, and 50 references.  Key Words: Bethesda classification, differentiated thyroid cancer, follicular thyroid cancer, papillary thyroid cancer, radioactive iodine, thyroid nodule, thyroidectomy

Sign in / Sign up

Export Citation Format

Share Document